Latest Breaking News On - Sukhjinder nijjer - Page 1 : vimarsana.com

December 17, 2020 When the 5-year results from the controversial EXCEL trial were published earlier this year, it revived an old and divisive stent-versus-surgery debate but it also rekindled questions about how clinical trials are funded. In addition to concerns over trial endpoints and reporting, some physicians complained that EXCEL and other device trials like it can’t be trusted because of the role of the manufacturer in funding the research. This story is part of Envision Change , an end-of-2020 series imagining a different future for cardiology, medicine, research, and health. SEE ALSO: Transforming Clinical Research, Remaking Medicine, Heroes to Human. The pros and cons of commercial funding in clinical research are well documented, and endless ink has been spent examining the ties between investigators and sponsors and the impact on clinical trials. But what’s the alternative? In a year when so many other aspects of cardiology practice and research have been upe

United statesUnited kingdomCity ofSukhjinder nijjerRichard kovacsJuan granadaAndrew foyKhurram nasirDavid brownAmerican heart associationBiomedical research centre at imperial college londonBritish cardiovascular societyMd washington university school of medicineBritish heart foundationPhd imperial college healthcareEuropean society of cardiology